Figure 1
Mortality in patients with positive and negative EHCTs
| Patients | Total | Solid tumours | Haematological tumours |
|---|---|---|---|
| EHCT+, all | 24 | 15 | 9 |
| EHCT+, dead (%) | 14 (58) | 7 (46) | 7 (78) |
| EHCT-, all | 30 | 18 | 12 |
| EHCT-, dead (%) | 16 (53) | 9 (50) | 7 (58) |
Distribution of ischemic and haemorrhagic lesions according to EHCTs indications
| Indications for EHCT | (+) EHCT (n = 32) | Ischemic stroke (n = 15) | Haemorrhagic lesions (n = 13) | p value |
|---|---|---|---|---|
| Altered mental status | 19 (59.4) | 11 (28.9) | 10 (26.3) | 0.80 |
| Focal deficits neurological | 13 (40.6) | 5 (23.8) | 6 (28.6) | 0.73 |
| Seizures | 5 (15.6) | 1 (14.3) | 1 (14.3) | - |
| Other | 3 (9.4) | 1 (6.2) | 0 (0.0) | - |
Characteristics of ECHTs
| Variables | EHCT (n = 64) | (+) EHCT (n = 32) | (-) EHCT (n = 32) | p value |
|---|---|---|---|---|
| Indications | ||||
| Altered mental status | 38 (59.4) | 19 (59.4) | 19 (59.4) | 1.00 |
| Focal deficits neurological | 21 (32.8) | 13 (40.6) | 8 (25.0) | 0.27 |
| Seizures | 7 (10.9) | 5 (15.6) | 2 (6.2) | 0.26 |
| Other | 16 (25.0) | 3 (9.4) | 13 (40.6) | < 0.01 |
| Results | ||||
| Ischemic stroke | 15 (23.4) | 15 (46.9) | ||
| Haemorrhagic lesions | 13 (20.3) | 13 (40.6) | ||
| Cerebral oedema | 10 (15.6) | 10 (31.2) | ||
| Brain metastases | 5 (7.8) | 5 (15.6) | ||
| CNS infiltrates | 1 (1.6) | 1 (3.1) | ||
| Arterio-malformation venous | 2 (3.1) | 2 (6.2) | ||
| Hydrocephalus | 1 (1.6) | 1 (3.1) | ||
| Primary brain tumour | 2 (3.1) | 2 (6.2) |
Mortality in patients with positive and negative EHCTs indicated for AMS
| Patients with AMS | Total | Solid tumours | Haematological |
|---|---|---|---|
| AMS & EHCT+, all | 13 | 6 | 7 |
| AMS & EHCT+, dead (%) | 10 (76) | 4 (67) | 6 (85) |
| AMS & EHCT-, all | 17 | 8 | 9 |
| AMS & EHCT-, dead (%) | 12(70) | 6 (75) | 6 (67) |
Characteristics of EHCT patients
| Variables | Overall (n = 54) | (+) EHCT (n = 24) | (-) EHCT (n = 30) | p value |
|---|---|---|---|---|
| Age | 61 (12.7) | 62 (13.2) | 60 (12.4) | 0.74 |
| Gender | ||||
| Male | 28 (51.9) | 16 (67.7) | 12 (40.0) | 0.05 |
| Female | 26 (48.1) | 8 (33.3) | 18 (60.0) | |
| Malignancy type | ||||
| Solid tumour | 33 (61.1) | 15 (62.5) | 18 (60.0) | 0.85 |
| malignancy Haematological | 21 (38.9) | 9 (37.5) | 12 (40.0) | |
| Outcome | ||||
| ICU LOS | 10.5 (6–14) | 8.5 (4–11) | 12.5 (7–15) | 0.03 |
| Hospital LOS | 18 (12–30) | 15.5 (10–26) | 20.0 (14–34) | 0.10 |
| ICU mortality | 30 (55.6) | 14 (58.3) | 16 (53.3) | 0.71 |